List of Contrave drug patents

Contrave is owned by Nalpropion.

Contrave contains Bupropion Hydrochloride; Naltrexone Hydrochloride.

Contrave has a total of 20 drug patents out of which 0 drug patents have expired.

Contrave was authorised for market use on 10 September, 2014.

Contrave is available in tablet, extended release;oral dosage forms.

Contrave can be used as use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity, for effect on blood glucose parameters in patients with insulin resistance, use of naltrexone and bupropion in a layered formulation for chronic weight management for affecting weight loss, for chronic weight management for treating overweight or obesity, use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder, use of naltrexone and bupropion based on an escalating dose schedule.

The generics of Contrave are possible to be released after 02 July, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11278544 NALPROPION Compositions for affecting weight loss
Apr, 2024

(1 year, 2 months from now)

US7462626 NALPROPION Compositions for affecting weight loss
Jul, 2024

(1 year, 5 months from now)

US8815889 NALPROPION Compositions and methods for increasing insulin sensitivity
Jul, 2024

(1 year, 5 months from now)

US7375111 NALPROPION Compositions for affecting weight loss
Mar, 2025

(2 years from now)

US9107837 NALPROPION Sustained release formulation of naltrexone
Jun, 2027

(4 years from now)

US8722085 NALPROPION Methods for administering weight loss medications
Nov, 2027

(4 years from now)

US9125868 NALPROPION Methods for administering weight loss medications
Nov, 2027

(4 years from now)

US10307376 NALPROPION Methods for administering weight loss medications
Nov, 2027

(4 years from now)

US8318788 NALPROPION Layered pharmaceutical formulations
Nov, 2027

(4 years from now)

US8088786 NALPROPION Layered pharmaceutical formulations
Feb, 2029

(6 years from now)

US11324741 NALPROPION Methods for treating visceral fat conditions
May, 2029

(6 years from now)

US8916195 NALPROPION Sustained release formulation of naltrexone
Feb, 2030

(7 years from now)

US11033543 NALPROPION Methods of providing weight loss therapy in patients with major depression
Jan, 2031

(7 years from now)

US9248123 NALPROPION Methods of providing weight loss therapy in patients with major depression
Jan, 2032

(8 years from now)

US10403170 NALPROPION Methods of treating overweight and obesity
Jun, 2033

(10 years from now)

US11139056 NALPROPION Methods of treating overweight and obesity
Jun, 2033

(10 years from now)

US9633575 NALPROPION Methods of treating overweight and obesity
Jun, 2033

(10 years from now)

US10828294 NALPROPION Compositions and methods for weight loss in at risk patient populations
Jul, 2034

(11 years from now)

US10835527 NALPROPION Compositions and methods for reducing major adverse cardiovascular events
Jul, 2034

(11 years from now)

US10231964 NALPROPION Compositions and methods for weight loss in at risk patient populations
Jul, 2034

(11 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity; For effect on blood glucose parameters in patients with insulin resistance; Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity; Use of naltrexone and bupropion based on an escalating dose schedule; Use of naltrexone and bupropion in a layered formulation for chronic weight management for affecting weight loss; Use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic